Shionogi To Invest In New Research Facility And Consolidate Kansai Bases
This article was originally published in PharmAsia News
Shionogi announced Jan. 28 plans to invest ¥14 billion toward building a new research facility in Fuchu, Osaka. Shionogi will consolidate its three research facilities currently spread throughout the Kansai area - Osaka City, Setsu City and Kouka City - and move around 700 researchers into the new facility, in which drug development and safety research will be conducted. The new facility is scheduled to begin operation in summer 2010. Takeda, another Osaka-based pharmaceutical giant, has set up a new research institute in Kanagawa prefecture. (Click here for more-Japanese language
You may also be interested in...
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.